Michael Sauter, MD
Neurology · Indiana, PANPI 1205837051
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $176,034 of the $272,797 with a category attached, or 64.5%. 60 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 25.1% of the total. Reporting peaked in 2024 at $54,587 and has fallen 70.8% since, to $15,959 in 2025. Among neurology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,730 payments — averaging $157.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$68K
- Teva Pharmaceuticals USA, Inc.$46K
- Bristol Myers Squibb$40K
- Eisai Inc.$35K
- Biogen$33K
- Amgen$12K
- plus $38K from 54 others
Across 3 payments — averaging $5428.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$14K
- Acadia Pharmaceuticals Inc$2K
What the payments were for
- Consulting fees$43,74416%
- Speaking & faculty fees$176,03465%
- Travel & lodging$21,0518%
- Food & beverage$31,30011%
- Education$6680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$272,797 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 40 | $335,439 |
| Austedo XrDeutetrabenazine | 34 | $194,126 |
| AustedoDeutetrabenazine | 36 | $190,700 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 29 | $157,069 |
| CopaxoneGlatiramer Acetate | 20 | $148,578 |
| FingolimodFingolimod Hcl | 23 | $145,275 |
| MayzentSiponimod | 13 | $124,473 |
| BetaseronInterferon Beta-1b | 11 | $105,561 |
| Teriflunomide | 20 | $69,819 |
| InbrijaLevodopa | 13 | $48,321 |
| AptiomEslicarbazepine Acetate | 29 | $40,404 |
| KeppraLevetiracetam | 24 | $39,317 |
| Nurtec OdtRimegepant Sulfate | 20 | $23,490 |
| Tegretol XrCarbamazepine | 22 | $20,906 |
| LeqembiLecanemab-Irmb | 11 | $19,831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Copaxone | $45,743 | $533,40490 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,051 | $335,43940 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $47 | $157,06929 claims |
| NovartisMayzent | $746 | $124,47313 claims |
| Acorda Therapeutics, IncInbrija | $228 | $48,32113 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $196 | $40,40429 claims |
| PfizerNurtec Odt | $817 | $23,49020 claims |
| Eisai Inc.Leqembi | $34,793 | $19,83111 claims |
| Johnson & JohnsonXarelto | $444 | $14,29923 claims |
| SK Life Science, Inc.Xcopri | $580 | $12,24711 claims |
| Upsher-smith Laboratories LLCTopiramate | $120 | $2,232146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Indiana
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Jill Giordano FarmerPhiladelphia$1.2M
- Ravi DukkipatiYork$936K
- Brad KleinAbington$927K
- Stephanie Nahas-GeigerPhiladelphia$786K
- John KhouryAbington$686K
- Amit Bar-OrPhiladelphia$596K
- Behrang SaminejadAllentown$594K
- Anoopum GuptaPittsburgh$592K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.